hbs

Voxelotor (GBT 440) is a novel hemoglobin S (HbS) polymerization inhibitor primarily used for the treatment of sickle cell disease (SCD) and a cytochrome P450 3A4 inhibitor. Voxelotor targets and covalently binds to the N-terminal valine of the HbS alpha chain, thereby stabilizing sickle cell hemoglobin (HbS).

Anti-HBsAg Antibody (OST 577) is a human-derived antibody expressed in CHO cells, targeting HBsAg. It comprises a huIgG1 heavy chain and a huλ light chain, with an estimated molecular weight (MW) of 144.46 kDa. The isotype control for Anti-HBsAg Antibody (OST 577) is HumanIgG1kappa, Isotype Control.

Aβ1-14-εK-HBsAg3 Th (UB311 immunogen II) is a bioactive peptide. It is one of the Aβ1–14 targeting peptides (B cell epitope) for UB-311.

Osivelotor is an allosteric modulator of hemoglobin S (HbS) [1].

PF-07059013, an orally active and potent noncovalent modulator of sickled hemoglobin (HbS), specifically binds to Hb with nanomolar affinity and demonstrates substantial partitioning into red blood cells (RBCs), making it useful for sickle cell disease (SCD) research [1][2].